drugset / Trial / NCT01435213
Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline
RandomizedSingle-groupSingle-blindBasic science
Summary
The purpose of this study is to validate \[11C\]ORM-13070 as an alpha2C-adrenoceptor imaging agent for human positron emission tomography (PET) studies of brain alpha2C-adrenoceptor occupancy.
Timeline
- Start
- 2011-09
- Primary completion
- 2012-01
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atipamezole | Small molecule | 5 ug | Intravenous |
| Subject | Atipamezole | Small molecule | 150 ug | Intravenous |
| Subject | Atomoxetine | Other / unclassified | 1.2 mg/kg | Oral |
| Subject | Insulin | Protein / enzyme biologic | — | Intravenous |
| Subject | Ketamine | Small molecule | 60 mg | Intravenous |
Indications
No indication recorded.